Oncobiologics (OTLK) Stock Price, News & Analysis

Company Overview

Oncobiologics, now known as Outlook Therapeutics, Inc. (NASDAQ: OTLK), is a biopharmaceutical company focused on developing and commercializing ophthalmic therapies for retinal diseases. The company was established as Oncobiologics and later changed its name to Outlook Therapeutics to reflect its emphasis on eye-care products.

Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab designed for intravitreal use. The therapy has been studied for vascular retinal conditions, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion. Outlook Therapeutics has also developed the product under the proposed brand name LYTENAVA.

The company’s activities have included clinical development, regulatory submissions and efforts to establish manufacturing and commercialization capabilities for ophthalmic biologics. Its programs are intended to serve patients and eye-care providers in the United States and international markets, subject to applicable regulatory approvals.

Key Stats

• Today's Range: $0.42 to $0.44
• 50-Day Range: $0.44 to $0.70
• 52-Week Range: $0.16 to $2.54
• Volume: 1.64 million shs
• Average Volume: 3.86 million shs
• Market Capitalization: $106.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.20
• Consensus Rating: Hold

Oncobiologics Stock Analysis - MarketRank™

Oncobiologics scored higher than 42% of companies evaluated by MarketBeat, and ranked 412th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Oncobiologics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Oncobiologics has a consensus price target of $5.20, representing about 1,091.6% upside from its current price of $0.44.

Amount of Analyst Coverage

Oncobiologics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oncobiologics are expected to grow in the coming year, from ($0.44) to ($0.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncobiologics is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncobiologics is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.63% of the float of Oncobiologics has been sold short.

Short Interest Ratio / Days to Cover

Oncobiologics has a short interest ratio ("days to cover") of 6.83.

Change versus previous month

Short interest in Oncobiologics has recently increased by 2.17%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncobiologics does not currently pay a dividend.

Dividend Growth

Oncobiologics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Oncobiologics this week, compared to 3 articles on an average week.

Search Interest

Only 12 people have searched for OTLK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

7 people have added Oncobiologics to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

Company Ownership

• Score: 3.1 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $2,499,999.00 in company stock, which represents 2.3531% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Oncobiologics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,499,999.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

1.80% of the stock of Oncobiologics is held by insiders.

Percentage Held by Institutions

11.20% of the stock of Oncobiologics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/07/2026
• Next Earnings (Estimated): 12/18/2026
• Fiscal Year End: 9/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:OTLK
• CIK: 1649989
• Web: www.outlooktherapeutics.com
• Phone: (609) 619-3990
• Fax: N/A
• Employees: 17
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Oncobiologics: $5.20
• High Price Target: $10.00
• Low Price Target: $1.60
• Potential Upside/Downside: +1,091.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$62.42 million
• Net Margins: N/A
• Pretax Margin: -18,772.37%
• Return on Equity: N/A
• Return on Assets: -254.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.81
• Quick Ratio: 0.63

Sales & Book Value

• Annual Sales: $1.35 million
• Price / Sales: 78.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.60) per share
• Price / Book: -0.73

Miscellaneous

• Outstanding Shares: 243,450,000
• Free Float: 239,066,000
• Market Cap: $106.24 million
• Optionable: Optionable
• Beta: 0.75